دورية أكاديمية
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
| العنوان: | A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. |
|---|---|
| المؤلفون: | Orth MF; Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Buecklein VL; Department of Internal Medicine III, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Kampmann E; Department of Internal Medicine III, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Subklewe M; Department of Internal Medicine III, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Noessner E; Institute of Molecular Immunology, Helmholtz Center, Munich, Germany., Cidre-Aranaz F; Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Romero-Pérez L; Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Wehweck FS; Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany.; Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Thalkirchner Str. 36, 80337, Munich, Germany., Lindner L; Department of Internal Medicine III, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Issels R; Department of Internal Medicine III, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany., Kirchner T; Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Thalkirchner Str. 36, 80337, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Altendorf-Hofmann A; Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University, Jena, Germany., Grünewald TGP; Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Munich, Germany. thomas.gruenewald@med.uni-muenchen.de.; Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Thalkirchner Str. 36, 80337, Munich, Germany. thomas.gruenewald@med.uni-muenchen.de.; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany. thomas.gruenewald@med.uni-muenchen.de.; German Cancer Research Center (DKFZ), Heidelberg, Germany. thomas.gruenewald@med.uni-muenchen.de., Knösel T; Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians University Munich, Thalkirchner Str. 36, 80337, Munich, Germany. thomas.knoesel@med.uni-muenchen.de. |
| المصدر: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2020 Jul; Vol. 69 (7), pp. 1353-1362. Date of Electronic Publication: 2020 Mar 28. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Berlin : Springer Verlag Original Publication: Berlin ; New York, NY : Springer International, c1982- |
| مواضيع طبية MeSH: | B7-H1 Antigen/*metabolism , Biomarkers, Tumor/*metabolism , Programmed Cell Death 1 Receptor/*metabolism , Sarcoma/*metabolism, Adolescent ; Adult ; Aged ; Cohort Studies ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Sarcoma/classification ; Sarcoma/pathology ; Survival Rate ; Young Adult |
| مستخلص: | Soft tissue sarcomas (STSs) are heterogeneous cancers associated with poor prognosis due to high rates of local recurrence and metastasis. The programmed death receptor ligand 1 (PD-L1) is expressed in several cancers. PD-L1 interacts with its receptor, PD-1, on the surface of tumor-infiltrating lymphocytes (TILs), thereby attenuating anti-cancer immune response. Immune checkpoint inhibitors targeting this interaction have been established as effective anti-cancer drugs. However, studies on the PD-L1 and PD-1 expression status in STS are commonly limited by small sample size, analysis of single STS subtypes, or lack of combinatorial marker assessment. To overcome these limitations, we evaluated the expression patterns of intratumoral PD-L1, the number of TILs, their PD-1 expression, and associations with clinicopathological parameters in a large and comprehensive cohort of 225 samples comprising six STS subtypes. We found that nearly all STS subtypes showed PD-L1 expression on the tumor cells, albeit with a broad range of positivity across subtypes (50% angiosarcomas to 3% synovial sarcomas). Co-expression and correlation analyses uncovered that PD-L1 expression was associated with more PD-1-positive TILs (P < 0.001), higher tumor grading (P = 0.016), and worse patients' 5-year overall survival (P = 0.028). The results were in line with several publications on single STS subtypes, especially when comparing findings for STS with low and high mutational burden. In sum, the substantial portion of PD-L1 positivity, the co-occurrence of PD-1-positive TILs, and the association of PD-L1 with unfavorable clinical outcome provide rationales for immune checkpoint inhibition in patients with PD-L1-positive STS. |
| References: | Pathology. 2017 Aug;49(5):506-513. (PMID: 28688724) J Clin Oncol. 2012 Jun 10;30(17):2046-54. (PMID: 22547592) Oncol Lett. 2011 Mar;2(2):315-318. (PMID: 22866083) Nature. 2020 Jan;577(7791):556-560. (PMID: 31942077) Oncol Res Treat. 2018;41(7-8):472-477. (PMID: 29895025) Cell. 2017 Nov 2;171(4):950-965.e28. (PMID: 29100075) Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505) Mol Cancer. 2018 Aug 23;17(1):129. (PMID: 30139382) BMC Immunol. 2019 Jan 11;20(1):4. (PMID: 30634925) ESMO Open. 2017 Jul 3;2(2):e000213. (PMID: 28761757) Oncoimmunology. 2016 Nov 4;6(1):e1253657. (PMID: 28197370) Oncoimmunology. 2017 Feb 8;6(3):e1278100. (PMID: 28405501) APMIS. 2018 Sep;126(9):746-754. (PMID: 30160021) Am Soc Clin Oncol Educ Book. 2018 May 23;38:925-938. (PMID: 30231352) Sarcoma. 2013;2013:168145. (PMID: 23554566) Int J Mol Sci. 2019 Sep 23;20(19):. (PMID: 31547532) Nat Rev Cancer. 2016 May;16(5):275-87. (PMID: 27079802) J Immunother Cancer. 2019 Aug 8;7(1):213. (PMID: 31395100) Cancer Res. 2017 Nov 1;77(21):e51-e54. (PMID: 29092939) Lancet Oncol. 2018 Mar;19(3):416-426. (PMID: 29370992) Oncotarget. 2017 Jul 11;8(35):59570-59580. (PMID: 28938660) Nature. 2020 Jan;577(7791):549-555. (PMID: 31942075) Onco Targets Ther. 2016 Aug 12;9:5023-39. (PMID: 27574444) Am Soc Clin Oncol Educ Book. 2018 May 23;38:910-915. (PMID: 30231383) Mod Pathol. 2019 Dec;32(12):1772-1785. (PMID: 31263176) J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443) J Transl Med. 2018 Nov 6;16(1):303. (PMID: 30400799) Cancer. 2017 Sep 1;123(17):3285-3290. (PMID: 28440953) Oncoimmunology. 2017 Nov 20;7(3):e1389366. (PMID: 29399389) Cancer Immunol Res. 2017 Feb;5(2):118-126. (PMID: 28039162) BMC Cancer. 2016 Jul 08;16:434. (PMID: 27393385) N Engl J Med. 2017 Dec 21;377(25):2500-2501. (PMID: 29262275) Nat Med. 2018 Jul;24(7):994-1004. (PMID: 29892065) Immunotherapy. 2018 Nov;10(15):1293-1302. (PMID: 30474476) Clin Cancer Res. 2020 Mar 15;26(6):1258-1266. (PMID: 31900276) Nat Med. 2007 Jan;13(1):84-8. (PMID: 17159987) Future Sci OA. 2018 Oct 04;4(10):FSO341. (PMID: 30457576) Br J Cancer. 2014 Mar 18;110(6):1456-64. (PMID: 24481401) Lancet Oncol. 2015 Mar;16(3):257-65. (PMID: 25704439) Oncotarget. 2017 Aug 4;9(2):1587-1601. (PMID: 29416716) N Engl J Med. 2015 Jan 22;372(4):311-9. (PMID: 25482239) Mol Cancer. 2019 Jan 15;18(1):10. (PMID: 30646912) Science. 2015 Apr 3;348(6230):56-61. (PMID: 25838373) |
| معلومات مُعتمدة: | 2016.167.1 Wilhelm Sander-Stiftung; 391665916 Deutsche Forschungsgemeinschaft; 70112257 Deutsche Krebshilfe |
| فهرسة مساهمة: | Keywords: Immune checkpoint inhibition; PD-1; PD-L1; Soft tissue sarcoma; Tumor-infiltrating lymphocytes |
| المشرفين على المادة: | 0 (B7-H1 Antigen) 0 (Biomarkers, Tumor) 0 (CD274 protein, human) 0 (PDCD1 protein, human) 0 (Programmed Cell Death 1 Receptor) |
| تواريخ الأحداث: | Date Created: 20200331 Date Completed: 20200630 Latest Revision: 20240426 |
| رمز التحديث: | 20240426 |
| مُعرف محوري في PubMed: | PMC11027659 |
| DOI: | 10.1007/s00262-020-02552-5 |
| PMID: | 32222780 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-020-02552-5 |